All In Biotech

Drug Trial Radar · NCT06642545

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

A Randomized, Open-label, Controlled, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With RC148 Versus Albumin-bound Paclitaxone Alone or in Combination With Toripalimab in Subjects With HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Feb 10, 2025

Primary completion

Oct 1, 2026

Study completion Oct 1, 2027

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluating the Efficacy of Disitamab Vedotin in Combination with RC148 Compared to Albumin-bound Paclitaxone Monotherapy or in Combination with Toripalimab for Subjects with HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer

Conditions

  • Breast Cancer

Interventions

  • Disitamab VedotinDrug

    Disitamab Vedotin 2.0mg/kg,intravenous infusion, every 2 weeks

  • RC148Drug

    20mg/kg, intravenous infusion, once every 2 weeks

  • Albumin-bound PaclitaxoneDrug

    125 mg/m2,intravenous infusion, D1-8, every 3 weeks

  • ToripalimabDrug

    240mg,intravenous infusion, once every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cance Hosoltal Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.